325.11

2.17% 6.89

Praxis Precision Medicines Inc (PRAX)

Overview News Price History Option Chain Financials Discussions Forecast

Praxis Precision Medicines Inc stock is traded at $325.11, with a volume of 338.90K. It is up +2.17% in the last 24 hours and up +7.18% over the past month. Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Previous Close:

$318.22

Open:

$321.78

24h Volume:

338.90K

Relative Volume:

0.55

Market Cap:

$9.05B

Revenue:

$1.77M

Net Income/Loss:

$-123.74M

P/E Ratio:

-35.45

EPS:

-9.17

Net Cash Flow:

$-95.21M

1W Performance:

-6.46%

1M Performance:

+7.18%

6M Performance:

+605.38%

1Y Performance:

+797.85%

1-Day Range:

$319.28

$332.57

1-Week Range:

$314.64

$354.87

52-Week Range:

$26.70

$356.00

Praxis Precision Medicines Inc Stock (PRAX) Company Profile

Name

Praxis Precision Medicines Inc

Sector

Healthcare (1106)

Industry

Biotechnology (621)

Phone

617-300-8460

Address

99 HIGH STREET, 30TH FLOOR, BOSTON

Employee

10,998

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

PRAX's Discussions on Twitter

Compare PRAX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PRAX Praxis Precision Medicines Inc	325.11	8.86B	1.77M	-123.74M	-95.21M	-9.17
VRTX Vertex Pharmaceuticals Inc	477.89	120.48B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	787.50	81.05B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	749.56	46.33B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	327.30	42.26B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	299.02	32.87B	5.36B	287.73M	924.18M	2.5229

Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-02-26	Initiated	Wells Fargo	Equal Weight
Dec-15-25	Reiterated	Oppenheimer	Outperform
Nov-19-25	Initiated	BTIG Research	Buy
Jun-02-25	Resumed	Oppenheimer	Outperform
May-07-25	Initiated	Chardan Capital Markets	Buy
Mar-03-25	Reiterated	H.C. Wainwright	Buy
Feb-11-25	Initiated	Deutsche Bank	Buy
Aug-05-24	Initiated	Oppenheimer	Outperform
Jun-24-24	Initiated	Needham	Buy
Jun-18-24	Initiated	Guggenheim	Buy
May-01-24	Initiated	Robert W. Baird	Outperform
Sep-19-23	Initiated	Truist	Buy
Jun-06-22	Downgrade	Wedbush	Outperform → Neutral
Dec-16-21	Initiated	H.C. Wainwright	Buy
Aug-26-21	Initiated	BofA Securities	Buy
Apr-26-21	Initiated	William Blair	Outperform
Nov-11-20	Initiated	Wedbush	Outperform
Nov-10-20	Initiated	Cowen	Outperform
Nov-10-20	Initiated	Evercore ISI	Outperform
Nov-10-20	Initiated	Piper Sandler	Overweight

View All

Praxis Precision Medicines Inc Stock (PRAX) Latest News

01:51 AM

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

01:51 AM

Mar 04, 2026

A Look At Praxis Precision Medicines (PRAX) Valuation After Wider Full Year And Q4 Net Loss - simplywall.st

Mar 04, 2026

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Mar 04, 2026

Biotech Praxis gives 2,931 stock units to 14 new employees - Stock Titan

Mar 04, 2026

Mar 03, 2026

PRAX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 03, 2026

Praxis Eyes Blockbuster Future As Precision Neurology Pipeline Matures - Citeline News & Insights

Mar 03, 2026

Feb 28, 2026

Why (PRAX) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Feb 28, 2026

GSA Capital Partners LLP Trims Stock Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat

Feb 28, 2026

Feb 27, 2026